The global narcolepsy drugs market size reached US$ 3.3 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 6.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.3% during 2023-2032.
Narcolepsy drugs refer to pharmaceutical medicines used for the treatment of chronic sleep disorders. The disorder is characterized by excessive daytime sleepiness (EDS), cataplexy or sudden loss of muscle strength, sleep paralysis, hallucinations, fragmented sleep and insomnia. Additional symptoms may include automatic behaviors without conscious awareness, blurred vision, double vision or droopy eyelids and disturbed mental functioning. Patients suffering from narcolepsy tend to sleep the same number of hours per day as normal individuals; however, sleep quality tends to be poorer. Some of the commonly used narcolepsy drugs include central nervous system stimulants, sodium oxybate, selective serotonin reuptake inhibitors and tricyclic antidepressants. These drugs aid in improving wakefulness in adult patients and minimizing hallucinations, sleepiness and cataplexy.
Narcolepsy without Cataplexy
Secondary Narcolepsy
Cataplexia
Others
Central Nervous System Stimulants
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitor
Others
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
What has been the impact of COVID-19 on the global narcolepsy drugs market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the disease type?
What is the breakup of the market based on the therapeutic type?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global narcolepsy drugs market and who are the key players?
What is the degree of competition in the industry?
Narcolepsy drugs refer to pharmaceutical medicines used for the treatment of chronic sleep disorders. The disorder is characterized by excessive daytime sleepiness (EDS), cataplexy or sudden loss of muscle strength, sleep paralysis, hallucinations, fragmented sleep and insomnia. Additional symptoms may include automatic behaviors without conscious awareness, blurred vision, double vision or droopy eyelids and disturbed mental functioning. Patients suffering from narcolepsy tend to sleep the same number of hours per day as normal individuals; however, sleep quality tends to be poorer. Some of the commonly used narcolepsy drugs include central nervous system stimulants, sodium oxybate, selective serotonin reuptake inhibitors and tricyclic antidepressants. These drugs aid in improving wakefulness in adult patients and minimizing hallucinations, sleepiness and cataplexy.
Narcolepsy Drugs Market Trends:
The increasing prevalence of narcolepsy across the globe is one of the key factors driving the growth of the market. This can be attributed to the sedentary lifestyles and hectic schedules of the working population, which, in turn, is significantly increasing the incidences of sleep-related disorders. Moreover, rising health consciousness among the masses and the increasing awareness regarding the available treatment alternatives are providing a thrust to the market growth. In line with this, the widespread adoption of sodium oxybate for the treatment of narcolepsy in children is also contributing to the growth of the market. Additionally, significant improvements in the diagnostic technologies for narcolepsy are acting as other growth-inducing factors. Pharmaceutical manufacturers are also developing variants with long-term benefits and reduced side effects. Other factors, including the rising geriatric population, which is more susceptible to such ailments, along with extensive research and development (R&D) activities in the field of neurology, are anticipated to drive the market toward growth.Key Market Segmentation:
The report provides an analysis of the key trends in each sub-segment of the global narcolepsy drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, disease type and therapeutic type.Breakup by Type:
Narcolepsy with CataplexyNarcolepsy without Cataplexy
Secondary Narcolepsy
Breakup by Disease Type:
Daytime Extreme SleepinessCataplexia
Others
Breakup by Therapeutic Type:
Sodium OxybateCentral Nervous System Stimulants
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitor
Others
Breakup by Region:
North AmericaUnited States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., Bioprojet Pharma, Graymark Healthcare Inc., Jazz Pharmaceuticals plc, Ligand Pharmaceuticals Incorporated, Novartis AG, SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.Key Questions Answered in This Report:
How has the global narcolepsy drugs market performed so far and how will it perform in the coming years?What has been the impact of COVID-19 on the global narcolepsy drugs market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the disease type?
What is the breakup of the market based on the therapeutic type?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global narcolepsy drugs market and who are the key players?
What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Narcolepsy Drugs Market
6 Market Breakup by Type
7 Market Breakup by Disease Type
8 Market Breakup by Therapeutic Type
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Avadel Pharmaceuticals plc
- Axsome Therapeutics Inc.
- Bioprojet Pharma
- Graymark Healthcare Inc.
- Jazz Pharmaceuticals plc
- Ligand Pharmaceuticals Incorporated
- Novartis AG
- SHIONOGI & Co. Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 147 |
| Published | July 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 3.3 Billion |
| Forecasted Market Value ( USD | $ 6.2 Billion |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
